Healthcare professionals

Real-world evidence

Links

From clinical to real-world evidence

Allergy immunotherapy (AIT) has evolved significantly over the last decade, triggered by the need for more evidence-based medicine. ALK has worked with the allergy community to develop the fields' most robust clinical trial programme, enrolling over 25,000 patients, enabling prescribing decisions to move from experience-based to evidence-based. But ideal-world evidence alone can only tell you so much.

That is where our programme Real-world Evidence in Allergy (REWEAL) comes in, demonstrating how AIT works in the real world.

REWEAL – best of both worlds

Comprising patient data from independent sources across multiple countries, REWEAL brings physicians best-in-class real-world evidence. It reveals the benefits of AIT for people with allergy – from improvements in quality of life and reduced drug burden to disease modification and other long-term outcomes.

Our goal is to help inform the right treatment decision by providing the best in both clinical and real-world evidence.

REWEAL – Real patients. Real questions. Answered

Have you ever

wondered if clinical

study outcomes of AIT

are generalisable to

the real world?

Time to REACT in AIT

With the REACT-study we aim to complement existing evidence from randomised controlled trials and address some key unanswered questions within AIT with real-world evidence. The study assesses the long-term effectiveness of AIT on both allergic rhinitis and asthma including more than 92,000 patients for up to nine years.